Home/Pipeline/Undisclosed Immune-Stimulating Degrader

Undisclosed Immune-Stimulating Degrader

Colorectal Cancer

PreclinicalActive

Key Facts

Indication

Colorectal Cancer

Phase

Preclinical

Status

Active

Company

Captor Therapeutics

About Captor Therapeutics

Captor Therapeutics is a clinical-stage biotech focused on unlocking the 'undruggable' proteome through targeted protein degradation. Founded in 2017 and publicly listed in Warsaw, the company has validated its scientific approach by securing substantial EU and Polish grant funding and advancing its lead MCL-1 degrader, CT-03, toward clinical trials. Its strategy combines world-class R&D in Wroclaw with strategic business development in Basel to build a leading European TPD franchise.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active
Program not named	Reponex	Pre-clinical	Active
Colorectal Cancer Screening Test	Metabiomics	Approved	Active